ArticleDermatology and therapy2026

Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis.

Marni Wiseman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.